Traws Pharma (TRAW)
Develops oral antivirals for influenza and COVID-19.
Something off on this page? Send us feedback.
Develops oral small-molecule antivirals for influenza and COVID-19 while retaining legacy oncology assets for partnering. Its virtual model relies on CROs, manufacturers, regulatory clearance, and partners because it has no approved products or internal commercial organization.
Develops oral small-molecule antivirals centered on tivoxavir marboxil for seasonal-influenza prevention and potential treatment, and ratutrelvir for COVID-19 without ritonavir. A preclinical two-component combination targets hantavirus, Ebola virus disease, and Lassa fever, while narazaciclib and rigosertib remain legacy oncology partnering assets.
Operates through CROs, clinical sites, and third-party manufacturers, with studies spanning Australia, a proposed United Kingdom challenge study, and U.S. FDA review. Tivoxavir's U.S. IND is on clinical hold pending toxicology and mutagenicity information, and the proposed UK study depends on additional safety data. With no approved products, manufacturing facility, or commercial organization, execution depends on regulatory clearance, external providers, and partners.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 18, 2026 | H.C. Wainwright | Target | Target: $8 | Target: $1 |
| Jun 18, 2026 | HC Wainwright & Co. | Downgrade | ||
| Jun 15, 2026 | Ladenburg Thalmann | Downgrade | ||
| Dec 3, 2025 | H.C. Wainwright | Target | Target: — | Target: $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $3.1M · Total debt $0 · Total assets $8.2M · Shareholders' equity −$5.3M
- Revenue
- $0
- Operating income
- −$6.9M
- Net income
- −$3.1M
No dividends on record.
| Institutions | 40.63% | 6.16M shares | |
|---|---|---|---|
| 34 holders · as of Jun 30, 2026 | |||
| Insiders | 4.61% | 698.9K shares | |
| 10 holders · as of Apr 8, 2026 | |||
| Other | 54.76% | 8.30M shares | |
| remainder | |||
15.15M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Orbimed Advisors LLCInstitution | 7.94% | 1.20M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 6.47% | 979,815 | filed May 15, 2026 |
Ally Bridge Group (NY) LLCInstitution | 5.19% | 786,236 | as of Jun 30, 2026 |
Adage Capital Partners GP, L.L.C.Institution | 4.82% | 730,000 | as of Jun 30, 2026 |
Adar1 Capital Management, LLCInstitution | 3.95% | 597,729 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Orbimed Advisors LLC | 10 percent owner | +3,586,374 | $1.67 |
- Pfizer
Direct oral COVID-19 rival through the PAXLOVID treatment franchise.
- Merck
COVID oral antiviral and long-acting influenza-prophylaxis competitor.
- Gilead Sciences
Approved COVID antiviral incumbent for overlapping at-risk patients.
- BioCryst Pharmaceuticals
Acute influenza-treatment competitor with the RAPIVAB franchise.
- GSK (ADR)
Inhaled influenza antiviral comparator through Relenza.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Traws Pharma | $0.4997 | −0.02% | $7.6M | — | — | — | +4,694.7% |
| Pfizer | $27.71 | −0.13% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Merck | $149.40 | −0.07% | $369.24B | 119.6 | 17.3 | 5.6 | +5.1% |
| Gilead Sciences | $149.68 | −0.58% | $186.93B | — | 16.5 | 6.1 | +10.2% |
| BioCryst Pharmaceuticals | $8.86 | +1.08% | $2.23B | — | 16.9 | 2.4 | +33.6% |
| GSK (ADR) | $50.55 | −1.05% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| Median | 36.7 | 16.5 | 2.5 | +5.3% |